Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Labcorp Genetics |
RCV001964634 | SCV002203934 | uncertain significance | Glycogen storage disease due to muscle and heart glycogen synthase deficiency | 2021-04-15 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. This sequence change replaces lysine with threonine at codon 381 of the GYS1 protein (p.Lys381Thr). The lysine residue is moderately conserved and there is a moderate physicochemical difference between lysine and threonine. This variant is not present in population databases (ExAC no frequency). This variant has not been reported in the literature in individuals with GYS1-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). |
| Ambry Genetics | RCV003167298 | SCV003903785 | uncertain significance | Inborn genetic diseases | 2023-02-22 | criteria provided, single submitter | clinical testing | The c.1142A>C (p.K381T) alteration is located in exon 8 (coding exon 8) of the GYS1 gene. This alteration results from a A to C substitution at nucleotide position 1142, causing the lysine (K) at amino acid position 381 to be replaced by a threonine (T). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |